CTLA4 and cancer: Given the roles of PD-1/PD-L1 and CTLA-4 in the Cancer-Immunity Cycle, CTLA-4 inhibitors initiates T cell activation, whereas PD-1/PD-L1 inhibitors are involved in the reactivation of effector responses in later stages.